ACE-031 (Ramatercept) is a fusion protein used in laboratory research models. This overview covers identity, documentation, and handling — not clinical use.
What is ACE-031?
ACE-031, known in research literature as Ramatercept, is a recombinant fusion protein combining the extracellular domain of the activin receptor type IIB (ActRIIB) with the Fc portion of human immunoglobulin G1 (IgG1). It is not a short synthesised peptide in the same class as BPC-157 or TB-500; it is a larger biological construct studied as a ligand-binding research tool.
Research context (laboratory models)
Published work has examined ACE-031 in cell and animal research models involving ActRIIB ligand pathways. Those papers describe molecular interactions under controlled experimental conditions. This article does not translate that literature into personal, athletic, or medical use advice.
It is important for researchers to know that clinical development of ACE-031 for human therapeutic use was discontinued after safety findings in trials. That history is relevant to risk assessment for research programmes and reinforces that catalogue material is not a medicine.
Supply form and handling
As a recombinant fusion protein, ACE-031 is structurally complex. Storage and handling requirements are typically more stringent than for small lyophilised peptides:
- Store lyophilised or archived material according to the CoA / product insert (often ultra-cold for long-term holdings)
- Keep vials sealed until required by your institutional protocol
- Protect from unnecessary light, heat, and humidity
- Log lot numbers carefully — essential for reproducibility with complex research materials
My UK Peptides does not publish mixing or reconstitution instructions. Follow your institution’s SOP for any laboratory preparation.
Research use context
ACE-031 from a research catalogue should be limited to in vitro or institutionally approved laboratory work. Follow your organisation’s biosafety and ethics rules for recombinant research materials.
Important: ACE-031 is a research-only compound. Human clinical development was discontinued due to adverse findings. This material is not for human or veterinary use under any circumstances.